1. |
Alsina M, Arrazubi V, Diez M, et al. Current developments in gastric cancer: from molecular profiling to treatment strategy. Nat Rev Gastroenterol Hepatol, 2023, 20(3): 155-170.
|
2. |
Zhan Z, Ji Y, Su H, et al. Discovery of 10 H-benzo[b] pyrido[2, 3- e][1, 4] oxazine AXL inhibitors via structure-based drug design targeting c-Met kinase. J Med Chem, 2023, 66(1): 220-234.
|
3. |
Storey CM, Altai M, Bicak M, et al. Quantitative in vivo imaging of the androgen receptor axis reveals degree of prostate cancer radiotherapy response. Mol Cancer Res, 2023, 21(4): 307-315.
|
4. |
Yoshimura A, Yamada T, Serizawa M, et al. High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib. Cancer Sci, 2023, 114(2): 606-618.
|
5. |
van Aalen EA, Wouters SFA, Verzijl D, et al. Bioluminescent RAPPID sensors for the single-step detection of soluble Axl and multiplex analysis of cell surface cancer biomarkers. Anal Chem, 2022, 94(17): 6548-6556.
|
6. |
Martínez-Bosch N, Cristóbal H, Iglesias M, et al. Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. EBioMedicine, 2022, 75: 103797. doi: 10.1016/j.ebiom.2021.103797.
|
7. |
Tsukamoto S, Sugi NH, Nishibata K, et al. ER-851, a novel selective inhibitor of AXL, overcomes resistance to antimitotic drugs. Mol Cancer Ther, 2023, 22(1): 12-24.
|
8. |
Bae D, Chaudhary P, Been JH, et al. Antitumor effect of 3-(quinolin-2-ylmethylene)-4, 6-dimethyl-5-hydroxy-7-azaoxindole down-regulating the Gas6-Axl axis. Eur J Med Chem, 2023, 251: 115274. doi: 10.1016/j.ejmech.2023.115274.
|
9. |
Liu E, Hjelle B, Bishop JM. Transforming genes in chronic myelogenous leukemia. Proc Natl Acad Sci U S A, 1988, 85(6): 1952-1956.
|
10. |
Goyette MA, Côté JF. AXL receptor tyrosine kinase as a promising therapeutic target directing multiple aspects of cancer progression and metastasis. Cancers (Basel), 2022, 14(3): 466. doi: 10.3390/cancers14030466.
|
11. |
Stitt TN, Conn G, Gore M, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell, 1995, 80(4): 661-670.
|
12. |
Mullen MM, Lomonosova E, Toboni MD, et al. GAS6/AXL inhibition enhances ovarian cancer sensitivity to chemotherapy and PARP inhibition through increased DNA damage and enhanced replication stress. Mol Cancer Res, 2022, 20(2): 265-279.
|
13. |
Zdżalik-Bielecka D, Kozik K, Poświata A, et al. Bemcentinib and gilteritinib inhibit cell growth and impair the endo-lysosomal and autophagy systems in an AXL-independent manner. Mol Cancer Res, 2022, 20(3): 446-455.
|
14. |
Malvankar C, Kumar D. AXL kinase inhibitors–A prospective model for medicinal chemistry strategies in anticancer drug discovery. Biochim Biophys Acta Rev Cancer, 2022, 1877(5): 188786. doi: 10.1016/j.bbcan.2022.188786.
|
15. |
Nasimian A, Al Ashiri L, Ahmed M, et al. A Receptor tyrosine kinase inhibitor sensitivity prediction model identifies AXL dependency in leukemia. Int J Mol Sci, 2023, 24(4): 3830. doi: 10.3390/ijms24043830.
|
16. |
Goyette MA, Duhamel S, Aubert L, et al. The receptor tyrosine kinase AXL is required at multiple steps of the metastatic cascade during HER2-positive breast cancer progression. Cell Rep, 2018, 23(5): 1476-1490.
|
17. |
Meyer AS, Miller MA, Gertler FB, et al. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci Signal, 2013, 6(287): ra66. doi: 10.1126/scisignal.2004155.
|
18. |
Lei T, Xu T, Zhang N, et al. Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis. Pharmacol Res, 2023, 188: 106668. doi: 10.1016/j.phrs.2023.106668.
|
19. |
Schieven SM, Traets JJH, Vliet AV, et al. The elongin BC complex negatively regulates AXL and marks a differentiated phenotype in melanoma. Mol Cancer Res, 2023, 21(5): 428-443.
|
20. |
Dharavath B, Butle A, Pal A, et al. Role of miR-944/MMP10/AXL- axis in lymph node metastasis in tongue cancer. Commun Biol, 2023, 6(1): 57. doi: 10.1038/s42003-023-04437-6.
|
21. |
Rizzi M, Tonello S, D’Onghia D, et al. Gas6/TAM axis involvement in modulating inflammation and fibrosis in COVID-19 patients. Int J Mol Sci, 2023, 24(2): 951. doi: 10.3390/ijms24020951.
|
22. |
Poświata A, Kozik K, Miączyńska M, et al. Endocytic trafficking of GAS6-AXL complexes is associated with sustained AKT activation. Cell Mol Life Sci, 2022, 79(6): 316. doi: 10.1007/s00018-022-04312-3.
|
23. |
Jung H, Lee SY, Lim S, et al. Anti-inflammatory clearance of amyloid-β by a chimeric Gas6 fusion protein. Nat Med, 2022, 28(9): 1802-1812.
|
24. |
Yong J, Elisabeth Groeger S, Ruf S, et al. Influence of leptin and compression in GAS-6 mediated homeostasis of periodontal ligament cell. Oral Dis, 2023, 29(3): 1172-1183.
|
25. |
Ma T, Huang R, Xu Y, et al. Plasma GAS6 predicts mortality risk in acute heart failure patients: insights from the DRAGON-HF trial. J Transl Med, 2023, 21(1): 21. doi: 10.1186/s12967-022-03859-w.
|
26. |
Xu TP, Ma P, Wang WY, et al. KLF5 and MYC modulated LINC00346 contributes to gastric cancer progression through acting as a competing endogeous RNA and indicates poor outcome. Cell Death Differ, 2019, 26(11): 2179-2193.
|
27. |
Zhang P, Dong Q, Zhu H, et al. Long non-coding antisense RNA GAS6-AS1 supports gastric cancer progression via increasing GAS6 expression. Gene, 2019, 696: 1-9.
|
28. |
Xia Y, Zhang R, Wang M, et al. Development and validation of a necroptosis-related gene prognostic score to predict prognosis and efficiency of immunotherapy in gastric cancer. Front Immunol, 2022, 13: 977338. doi: 10.3389/fimmu.2022.977338.
|
29. |
Bae CA, Ham IH, Oh HJ, et al. Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma. Gastric Cancer, 2020, 23(5): 824-836.
|
30. |
Yoshioka T, Shien K, Takeda T, et al. Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells. Cancer Sci, 2019, 110(8): 2549-2557.
|
31. |
Chen T, Chen J, Zeng T, et al. WZ35 inhibits gastric cancer cell metastasis by depleting glutathione to promote cellular metabolic remodeling. Cancer Lett, 2023, 555: 216044. doi: 10.1016/j.canlet.2022.216044.
|
32. |
Choueiri TK, McDermott DF, Merchan J, et al. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. Lancet Oncol, 2023, 24(5): 553-562.
|
33. |
Terry S, Dalban C, Rioux-Leclercq N, et al. Association of AXL and PD-L1 expression with clinical outcomes in patients with advanced renal cell carcinoma treated with PD-1 Blockade. Clin Cancer Res, 2021, 27(24): 6749-6760.
|
34. |
Apolo AB, Nadal R, Tomita Y, et al. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. Lancet Oncol, 2020, 21(8): 1099-1109.
|
35. |
Huang M, Chen M, Qi M, et al. Perivascular cell-derived extracellular vesicles stimulate colorectal cancer revascularization after withdrawal of antiangiogenic drugs. J Extracell Vesicles, 2021, 10(7): e12096. doi: 10.1002/jev2.12096.
|
36. |
Huang M, Liu M, Huang D, et al. Tumor perivascular cell-derived extracellular vesicles promote angiogenesis via the Gas6/Axl pathway. Cancer Lett, 2022, 524: 131-143.
|
37. |
Yokoyama Y, Lew ED, Seelige R, et al. Immuno-oncological efficacy of RXDX-106, a novel TAM (TYRO3, AXL, MER) family small-molecule kinase inhibitor. Cancer Res, 2019, 79(8): 1996-2008.
|
38. |
Cardone C, Blauensteiner B, Moreno-Viedma V, et al. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. Eur J Cancer, 2020, 138: 1-10.
|
39. |
Solanes-Casado S, Cebrián A, Rodríguez-Remírez M, et al. Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer. Biomed Pharmacother, 2021, 144: 112347. doi: 10.1016/j.biopha.2021.112347.
|
40. |
Kawasaki Y, Miyamoto M, Oda T, et al. The novel lncRNA CALIC upregulates AXL to promote colon cancer metastasis. EMBO Rep, 2019, 20(8): e47052. doi: 10.15252/embr.201847052.
|
41. |
Ciardiello D, Blauensteiner B, Matrone N, et al. Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. Med Oncol, 2021, 38(3): 24. doi: 10.1007/s12032-021-01464-3.
|
42. |
Liao YY, Chuang YT, Lin HY, et al. GALNT2 promotes invasiveness of colorectal cancer cells partly through AXL. Mol Oncol, 2023, 17(1): 119-133.
|
43. |
Chen Q, Zhou L, Ma D, et al. LncRNA GAS6-AS1 facilitates tumorigenesis and metastasis of colorectal cancer by regulating TRIM14 through miR-370-3p/miR-1296-5p and FUS. J Transl Med, 2022, 20(1): 356. doi: 10.1186/s12967-022-03550-0.
|
44. |
Lu Y, Wang W, Liu Z, et al. Long non-coding RNA profile study identifies a metabolism-related signature for colorectal cancer. Mol Med, 2021, 27(1): 83. doi: 10.1186/s10020-021-00343-x.
|
45. |
de Souza Oliveira PF, Faria AVS, Clerici SP, et al. Violacein negatively modulates the colorectal cancer survival and epithelial-mesenchymal transition. J Cell Biochem, 2022, 123(7): 1247-1258.
|
46. |
Chen D, Wang R, Long M, et al. Identification of in vitro and in vivo oncolytic effect in colorectal cancer cells by Orf virus strain NA1/11. Oncol Rep, 2021, 45(2): 535-546.
|